 |
| Corporate Health |
|
|
Nationwide Corporate Flu Program
 | Influenza
|
Information provided by 
The influenza vaccine has proven to be effective in significantly reducing the more serious consequences of the influenza virus.
| Worldwide impact of immunization |
Immunization of subjects aged 65 and older has led a 31 to 70% decrease in the number of hospitalizations and a 31 to 68% decrease in mortality.
The more serious the direct or induced effects of influenza (complications of infection in high-risk individuals or even death) the greater the protection conferred.
This is particularly true given the fact that the influenza virus renders the subject more vulnerable to other infections, including pneumococcus, staphylococcus or H. influenzae, explains why the vaccine is able to confer protection against child pneumonia or acute otitis.
The vaccine's ability to significantly curb the number of serious consequences and thus reduce medical costs of the illness is well documented. Studies have shown that the savings in direct costs alone (ambulance, hospitalization - whether complications proved fatal or not) are greater than the costs of vaccinating all individuals over 65 and other high-risk patients (27, p.155).
